. 2021 Sep 10;25(12):3244–3257. doi: 10.1007/s11605-021-05115-w

Table 2.

Summary of published studies examining the use of TOC for radioguided surgery

Author	Ref	Number of cases	Tumour type	Tumour location	R’pharm	Peptide mass (ug)	Activity (MBq)	Delay	Results	Comments
Maccauro et al	²²	3	MGC	Midgut	TOC	N/S	185	4 h	All primaries identified and excised Nodes: TP 35, TN 72, FP 0, FN 0	Includes detection of an extra-regional node
		1	Rectal	Rectal
		1	Gastric NEC	Stomach
Hodolič et al	²³	5	MGC	Midgut	TOC	20*	550–650	3–6 h	Identified 5/5	*Amount of peptide prepared 11/16 tumours located in pancreas on imaging
		4	Insulinoma	Pancreas					Identified 2/4
		3	Gastrinoma	Pancreas					Identified 1/3
		4	NEC	Pancreas					Identified 3/4
Hubalewska-Dydejczyk et al	²⁴	5	Carcinoid	Not stated	TATE	10	700	24 h	Not stated
Hubalewska-Dydejczyk et al	²⁵	4	Carcinoid	Midgut	TATE	10	700	24 h	RGS: 3/3 tumours, 7/8 nodes, 1 FP SRS: 3/3 tumours, 3/8 nodes, 1FP	Peptide dose based on administration of half of 20 ug of peptide in kit
Hubalewska-Dydejczyk et al	²⁵	5	Pancreatic	Pancreas	TATE	10	700	24 h	RGS: 5/5 tumours SRS: 5/5 tumours
Fettich et al	²⁶	2	Gastrinoma	Not Stated	TOC	10	600	4 h	Identified all tumours with TBR of > 3
		1	Insulinoma	Pancreas
		1	Carcinoid	Not stated

MGC midgut carcinoma, NEC neuroendocrine carcinoma, TOC ^99mTc.EDDA/HYNIC-TOC, TATE ^99mTc.EDDA/HYNIC-octreotate, N/S not stated, RGS radioguided surgery, TP true positive, TN true negative, FP false positive, FN false negative